Damon Dierker, OD, FAAO, Director of Clinical Strategy & Optometric Services at Eye Surgeons of Indiana, hosted Jerry Robben, OD, chief optometrist and director of clinical research at Bowden Eye and Associates in Jacksonville, Florida, and adjunct clinical assistant professor at the Arizona College of Optometry, for a
Dry Eye Fireside Chat on tear film biomarkers.
More than a decade ago, Dr. Robben’s first matrix metalloproteinase 9 (MMP-9) test contradicted his slit lamp exam. Today, his team runs osmolarity and MMP-9 on every
suspected dry eye patient before the doctor walks in. Osmolarity anchors the diagnosis and the follow-up, and MMP-9 exposes inflammation that a quiet-looking eye can hide.
“With the first patient, I was dead wrong. I wouldn’t have added an immunomodulator or a steroid. The symptoms weren’t off the charts, but the MMP-9 was positive. And it completely changed what I was going to do for that patient that day; we did add an immunomodulator.”
Tear film biomarkers in DED fast facts
- Start with a questionnaire: A SPEED (Standardized Patient Evaluation of Eye Dryness) score of 1 or higher
- Monitor results: If you can run only one point-of-care test, run osmolarity, and repeat it at follow-up to track trends.
- DEWS III diagnosis: Per the Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) III, symptoms plus one of: noninvasive tear breakup time (NITBUT) under 10 seconds; osmolarity ≥308 mOsm/L or an interocular difference above 8 mOsm/L; or ocular surface staining1
- MMP-9 (in trial): 85% sensitivity and 94% specificity2
- MMP-9 (in practice): 70% to 81% sensitivity and 38% specificity3
- Interpreting findings: Let abnormal results point to the cause. A hyperosmolar, inflamed eye often needs MGD addressed, not just another drop.
What MMP-9 catches, and what it misses
Dr. Robben had assumed he could spot inflammation at the slit lamp. The patient’s symptoms were modest, yet the strip came back positive, so he started a loteprednol etabonate (Lotemax) pulse. A positive strip means tear MMP-9 is at or above 40 ng/mL,3 which Dr. Robben reads as a sign that epithelial cells are being damaged.
The original trial reported 85% sensitivity and 94% specificity across 143 patients with dry eye and 63 healthy controls.2 A 2025 analysis of 1,515 patients at a Bogotá dry eye clinic found 81% sensitivity against the trial’s criteria.3
Those criteria required an Ocular Surface Disease Index (OSDI) score of 13 or higher, Schirmer under 10 mm, breakup time under 10 seconds, and staining all at once. Against the broader TFOS DEWS II criteria, sensitivity fell to 70%, with 38% specificity under both. The authors cautioned that the test should not be used on its own to diagnose dry eye, because it misses milder disease.3
Osmolarity as the intraocular pressure of dry eye
Under TFOS DEWS III, a positive symptom screen plus any one abnormal sign confirms dry eye: NITBUT under 10 seconds,
osmolarity of 308 mOsm/L or higher in either eye (or an interocular difference above 8 mOsm/L), or
ocular surface staining.
1 MMP-9 is not one of the criteria.
“For me osmolarity is kind of like IOP in glaucoma. We check it once a patient’s established they have dry eye, we check it every time they come in. We’re looking for trends.”
As Dr. Dierker notes, osmolarity tells you there is a problem but not why. A high reading means the tear film is too concentrated, either because too little aqueous is produced or because too much evaporates, and Dr. Robben says the likeliest culprit is
meibomian gland dysfunction (MGD). For Dr. Dierker, a symptomatic MGD patient with a positive MMP-9 is often a fast track to an
intense pulsed light (IPL) discussion.
“When you have MGD, you have blocked glands and until you address that, you’re just ignoring the problem and pacifying it.”
Building the workflow
At Bowden Eye and Associates, a SPEED score of 1 or higher sends technicians to run osmolarity, MMP-9,
meibography, and a lipid layer or dynamic breakup measurement as standing orders. Osmolarity repeats at nearly every visit; MMP-9 repeats at complete exams, with new symptoms, or to confirm treatment worked.
Dr. Robben uses the questionnaire as evidence—a patient may report feeling “about the same” at 6 weeks while their SPEED score has dropped from 8 to 2, and that number changes the conversation.
This article was written by Keren Beki based on the recorded conversation between Drs. Dierker and Robben.
Want this episode in podcast form? Subscribe to Dry Eye Fireside Chat on your favorite podcasting platforms!